- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cancer Gene May Be Linked to Obesity
A gene known to cause cancer may also play a role in determining obesity, according to researchers at the Virginia Commonwealth University Massey Cancer Center.
A gene known to cause cancer, Astrocyte elevated gene-1 (AEG-1), may also play a role in determining obesity, according to researchers at the Virginia Commonwealth University Massey Cancer Center. AEG-1 could even be controlled with certain therapies to prevent or reverse obesity and obesity-related cancers.
In a series of papers published in Journal of Biological Chemistry and Bioconjugate Chemistry, the Massey researchers describe the creation of a novel therapy that inhibits AEG-1 and stops the growth of liver cancer cells; show that AEG-1 blocks thyroid hormone function and contributes to nonthyroidal illness syndrome; and find that AEG-1 may play a key role in regulating fat metabolism.
Devanand Sarkar, PhD, and colleagues found that the absence of AEG-1 leads to increased activity of several factors in the intestines that prevents absorption of fat. Mice without AEG-1 stay lean and live longer.
“Fatty liver is a main cause of liver cancer, so we have that direct correlation between liver cancer and obesity,” Dr Sarkar said in a statement. “This also is important because we now know that all cancers can be caused by obesity.”
In preclinical lab experiments, researchers used nanoparticles to develop a system to deliver the combination intravenously to mice with transplanted human liver cancer cells.
“What we found is that the tumor disappears,” Dr Sarkar said. “Anything delivered intravenously goes to the liver first, so the success of our experiments suggests that this might also be an effective way to treat liver cancer in human patients.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
